| 鲍磊 钟金妹 严明科 马进 储珉.美罗培南不同输注方案治疗老年ICU获得性重症肺炎的临床研究[J].,2014,14(30):5963-5965 |
| 美罗培南不同输注方案治疗老年ICU获得性重症肺炎的临床研究 |
| Clinical Studies of Different Infusion Regimens of Meropenemin Elderly ICU-Acquired Severe Pneumonia |
| |
| DOI： |
| 中文关键词: 美罗培南 ICU 获得性重症肺炎 老年 |
| 英文关键词: Meropenem ICU-acquired severe pneumonia Elderly |
| 基金项目: |
|
| 摘要点击次数: 683 |
| 全文下载次数: 744 |
| 中文摘要: |
| 目的：探讨美罗培南不同输注方案治疗老年ICU获得性重症肺炎的临床效果。方法：选取2011 年6 月至2014 年1 月我院
的92 例老年ICU 获得性重症肺炎患者，随机分为传统组和改良组，每组各46 例，分别采用不同的输注速度给予美罗培南治疗，
并且对其总有效率、细菌学疗效进行评定，观察记录患者的不良反应情况、住院时间及抗菌药物的治疗费用。结果：改良组患者的
总有效率为82.61％，显著高于传统组的67.39％（P<0.05）；改良组患者的细菌学疗效明显优于传统组（P<0.05）；改良组患者的治
疗时间为（5.94± 1.21）d，明显低于传统组的（7.52± 1.47）d（P<0.05）；改良组患者的治疗费用为（3412.7± 992.4）元，相比于传统组
的（3983.5± 1022.6）元明显降低，差异均有统计学意义（P<0.05）。两组患者分别有3 例出现不良反应，其中，4 例出现腹泻，2 例出
现恶心，但患者均能够耐受，停药后腹泻、恶心症状消失，差异无统计学意义（P＞0.05）。结论：美罗培南治疗ICU 获得性重症肺炎
在提高临床治疗效果、减轻患者的炎症反应、缩短治疗时间，在一定程度上能够降低患者的经济负担方面具有显著的优越性。 |
| 英文摘要: |
| Objective:To explore the clinical effects of different meropenem infusion regimens in elderly ICU-acquired severe
pneumonia.Methods:92 cases of elderly patients with ICU-acquired severe pneumonia in our hospital from June 2011 to January 2014
were randomly divided into traditional group and improved group, with 46 cases in each group. Two groups of patients were given
different rates of meropenem infusion, and the total efficiency, bacteriological efficacy were evaluated, and the adverse reactions, length
of stay, antimicrobial treatment costs were observed and recorded in two groups.Results:The total efficiency of the improved group was
82.61%, significantly higher than that of the traditional group (67.39%) (P<0.05); The improved group was significantly better than
traditional group in the bacteriological efficacy (P<0.05); Length of stay and antimicrobial treatment costs in improved group were
(5.94± 1.21) d and (3412.7± 992.4) million yuan, significantly lower than those of the traditional group (7.52± 1.47) d; (3983.5±
1022.6) million (all P<0.05). There were 3 cases with adverse reactions in each group, including 4 cases of diarrhea and 2 cases of
nausea, which could be tolerated by patients. These adverse reactions which had no significant difference (P＞0.05) disappeared after the
stop of medication.Conclusion:Meropenem presents significant advantages in improving clinical outcomes in ICU acquired severe
pneumonia, and can reduce inflammation in patients, shorten the treatment time, have the distinct advantages to reduce the economic
burden of patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
